Theodosia Maina

List of Publications by Year in Descending Order

100 papers	2,667 citations	27 h-index	47 g-index
108 ext. papers	2,980 ext. citations	5.2 avg, IF	4.73 L-index

#	Paper	IF	Citations
100	Radiolabeled Bombesin Analogs. *Cancers*, **2021**, 13,	6.6	9
99	[Tc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes. *Cancers*, **2021**, 13,	6.6	3
98	GRPr Antagonist Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients. *Journal of Nuclear Medicine*, **2021**, 62, 1517-1523	8.9	3
97	SPECT Radiochemistry **2021**, 479-492		
96	[Tc]Tc-DGA1, a Promising CCKR-Antagonist-Based Tracer for Tumor Diagnosis with Single-Photon Emission Computed Tomography. *Molecular Pharmaceutics*, **2020**, 17, 3116-3128	5.6	2
95	Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands. *Pharmaceutics*, **2020**, 12,	6.4	3
94	Imaging of inflammatory cellular protagonists in human atherosclerosis: a dual-isotope SPECT approach. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 2856-2865	8.8	4
93	Optimizing the Profile of [Tc]Tc-NT(7-13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
92	[Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models. *Molecules*, **2020**, 25,	4.8	6
91	One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [Tc]Tc-DB4 and [In]In-SG4 in Mice Treated with Entresto. *Pharmaceutics*, **2020**, 12,	6.4	1
90	Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist Lu-DOTAGA-PEG -RM26. *International Journal of Cancer*, **2019**, 145, 3347-3358	7.5	14
89	Comparing Gly/dAla-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the In-SB3/In-SB4 Radiotracer Pair. *Molecules*, **2019**, 24,	4.8	7
88	Localization of Tc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses. *Pharmaceuticals*, **2019**, 12,	5.2	5
87	Comparative evaluation of the new GRPR-antagonist In-SB9 and In-AMBA in prostate cancer models: Implications of in vivo stability. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2019**, 62, 646-655	1.9	5
86	Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2019**, 62, 673-683	1.9	19
85	Instant kit preparation of Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [Ga]Ga-DATA-TOC. *EJNMMI Research*, **2019**, 9, 48	3.6	16
84	From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies. *Seminars in Nuclear Medicine*, **2019**, 49, 422-437	5.4	19

83	Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin. *Bioconjugate Chemistry*, **2018**, 29, 1774-1784	6.3	19
82	In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer. *Molecular Imaging and Biology*, **2018**, 20, 973-983	3.8	8
81	New Gastrin Releasing Peptide Receptor-Directed [Tc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation. *Journal of Medicinal Chemistry*, **2018**, 61, 3138-3150	8.3	14
80	A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study. *Polish Archives of Internal Medicine*, **2018**, 128, 791-795	1.9	9
79	Electrospray ionization study of tricarbonyl fac-[Re(CO) (PO)(X)]-type complexes: influence of ancillary co-ligands in the release of carbon monoxide. *Rapid Communications in Mass Spectrometry*, **2018**, 32, 1199-1206	2.2	1
78	From Bench to Bed: New Gastrin-Releasing Peptide Receptor-Directed Radioligands and Their Use in Prostate Cancer. *PET Clinics*, **2017**, 12, 205-217	2.2	22
77	Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors. *Nuclear Medicine and Biology*, **2017**, 52, 57-62	2.1	12
76	Theranostic Prospects of Gastrin-Releasing Peptide Receptor-Radioantagonists in Oncology. *PET Clinics*, **2017**, 12, 297-309	2.2	33
75	Rhenium(I) Tricarbonyl Complexes with (2-Hydroxyphenyl)diphenylphosphine as PO Bidentate Ligand. *Inorganic Chemistry*, **2017**, 56, 8175-8186	5.1	19
74	Novel bifunctional DATA chelator for quick access to site-directed PET Ga-radiotracers: preclinical proof-of-principle with [Tyr]octreotide. *Dalton Transactions*, **2017**, 46, 14584-14590	4.3	11
73	Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results. *Journal of Nuclear Medicine*, **2017**, 58, 75-80	8.9	88
72	68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. *Journal of Nuclear Medicine*, **2017**, 58, 293-299	8.9	63
71	NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice. *Molecules*, **2017**, 22,	4.8	19
70	Preclinical in vivo cancer, straightway to patients?. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 61, 145-152	1.4	2
69	Improved Quantification of the Beta Cell Mass after Pancreas Visualization with Tc-demobesin-4 and Beta Cell Imaging with In-exendin-3 in Rodents. *Molecular Pharmaceutics*, **2016**, 13, 3478-3483	5.6	8
68	Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients. *European Journal of Pharmaceutical Sciences*, **2016**, 91, 236-42	5.1	27
67	Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translation. *EJNMMI Research*, **2016**, 6, 15	3.6	16
66	Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [Ga]SB3 and PET/CT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 964-973	8.8	69

65	Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon. *Cancer Biotherapy and Radiopharmaceuticals*, **2016**, 31, 20-8	3.9	18
64	From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial. *European Journal of Pharmaceutical Sciences*, **2016**, 85, 1-9	5.1	20
63	In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies. *Theranostics*, **2016**, 6, 104-17	12.1	40
62	(99m)Tc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice. *Nuclear Medicine and Biology*, **2016**, 43, 347-54	2.1	11
61	In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer. *Journal of Nuclear Medicine*, **2015**, 56, 752-7	8.9	39
60	Somatostatin Analogs **2015**, 291-305		
59	In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligands. *Nuclear Medicine and Biology*, **2015**, 42, 824-32	2.1	11
58	Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 59, 287-302	1.4	18
57	In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice. *Cancer Biotherapy and Radiopharmaceuticals*, **2014**, 29, 359-67	3.9	9
56	"To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting. *Journal of Nuclear Medicine*, **2014**, 55, 121-7	8.9	76
55	[111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors. *Journal of Medicinal Chemistry*, **2014**, 57, 6564-71	8.3	14
54	[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting. *European Journal of Medicinal Chemistry*, **2014**, 73, 30-7	6.8	9
53	GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man study. *Molecular Imaging and Biology*, **2014**, 16, 888-95	3.8	38
52	Tumor diagnosis with new 111In-radioligands based on truncated human gastrin releasing peptide sequences: synthesis and preclinical comparison. *Journal of Medicinal Chemistry*, **2013**, 56, 8579-87	8.3	10
51	Gastrin releasing peptide receptor-directed radioligands based on a bombesin antagonist: synthesis, (111)in-labeling, and preclinical profile. *Journal of Medicinal Chemistry*, **2013**, 56, 2374-84	8.3	22
50	99mTc radiotracers based on human GRP(18-27): synthesis and comparative evaluation. *Journal of Nuclear Medicine*, **2013**, 54, 1797-803	8.9	16
49	[(99m)Tc]Demomedin C, a radioligand based on human gastrin releasing peptide(18-27): synthesis and preclinical evaluation in gastrin releasing peptide receptor-expressing models. *Journal of Medicinal Chemistry*, **2012**, 55, 8364-74	8.3	12
48	[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. *EJNMMI Research*, **2012**, 2, 25	3.6	19

47	Tetraamine-coupled peptides and resulting (99m)Tc-radioligands: an effective route for receptor-targeted diagnostic imaging of human tumors. *Current Topics in Medicinal Chemistry*, **2012**, 12, 2655-67	3	21
46	Distribution, elimination, and renal handling of (99m)technetium-Demogastrin 1. *Cancer Biotherapy and Radiopharmaceuticals*, **2012**, 27, 169-74	3.9	1
45	[99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study. *Cancer Biotherapy and Radiopharmaceuticals*, **2011**, 26, 557-63	3.9	13
44	Comparative biodistribution of 12 □□□In-labelled gastrin/CCK2 receptor-targeting peptides. *European Journal of Nuclear Medicine and Molecular Imaging*, **2011**, 38, 1410-6	8.8	74
43	Comparison of the binding and internalization properties of 12 DOTA-coupled and □□□In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. *European Journal of Nuclear Medicine and Molecular Imaging*, **2011**, 38, 1417-25	8.8	54
42	Intramolecular azo-bridge as a cystine disulfide bond surrogate: Somatostatin-14 and brain natriuretic peptide (BNP) analogs. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 798-806	3.4	2
41	Of mice and humans: are they the same?--Implications in cancer translational research. *Journal of Nuclear Medicine*, **2010**, 51, 501-4	8.9	124
40	Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 1265-72	8.8	64
39	Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. *Nuclear Medicine and Biology*, **2008**, 35, 839-49	2.1	46
38	Bombesin receptor antagonists may be preferable to agonists for tumor targeting. *Journal of Nuclear Medicine*, **2008**, 49, 318-26	8.9	217
37	Synthesis and sst(2) binding profiles of new [Tyr(3)]octreotate analogs. *Journal of Peptide Science*, **2008**, 14, 725-30	2.1	3
36	GnRH analogues containing conformationally restricted amino acids in positions 3 and 6: differential impact on pituitary binding affinity and direct antiproliferative effect on breast cancer cells□*Chemical Biology and Drug Design*, **2008**, 66, 57-64		9
35	[99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results. *European Journal of Nuclear Medicine and Molecular Imaging*, **2007**, 34, 1804-14	8.8	31
34	Synthesis and Biological Evaluation of New GnRH Analogues on Pituitary and Breast Cancer Cells. *International Journal of Peptide Research and Therapeutics*, **2007**, 13, 143-149	2.1	3
33	Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats. *Anticancer Research*, **2007**, 27, 907-12	2.3	11
32	[(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 831-40	8.8	22
31	Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. *Journal of Medicinal Chemistry*, **2006**, 49, 4767-76	8.3	41
30	Targeting prostate cancer with radiolabelled bombesins. *Cancer Imaging*, **2006**, 6, 153-7	5.6	40

29	Tetraamine-modified octreotide and octreotate: labeling with 99mTc and preclinical comparison in AR4-2J cells and AR4-2J tumor-bearing mice. *Journal of Peptide Science*, **2006**, 12, 124-31	2.1	13
28	Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. *Journal of Medicinal Chemistry*, **2005**, 48, 100-10	8.3	138
27	99mTc demotate 1: biodistribution and elimination characteristics in rats. *Nuclear Medicine Communications*, **2005**, 26, 549-54	1.6	3
26	3D solution structure of [Tyr3]octreotate derivatives in DMSO: structure differentiation of peptide core due to chelate group attachment and biologically active conformation. *Medicinal Chemistry*, **2005**, 1, 487-99	1.8	5
25	Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. *Journal of Nuclear Medicine*, **2005**, 46, 823-30	8.9	47
24	CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. *Journal of Nuclear Medicine*, **2005**, 46, 1727-36	8.9	69
23	99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. *Cancer Biotherapy and Radiopharmaceuticals*, **2004**, 19, 73-9	3.9	22
22	[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. *European Journal of Nuclear Medicine and Molecular Imaging*, **2003**, 30, 247-58	8.8	156
21	Molecular gastrin receptor localisation in mice using high-resolution SPET-MRI image fusion. *European Journal of Nuclear Medicine and Molecular Imaging*, **2003**, 30, 800	8.8	5
20	99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. *European Journal of Nuclear Medicine and Molecular Imaging*, **2003**, 30, 1211-9	8.8	48
19	[99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. *European Journal of Nuclear Medicine and Molecular Imaging*, **2002**, 29, 742-53	8.8	85
18	Novel lipophilic amidate oxorhenium and oxotechnetium complexes as potential brain agents: synthesis, characterization and biological evaluation. *Journal of Biological Inorganic Chemistry*, **2001**, 6, 159-65	3.7	14
17	Development of novel mixed-ligand oxotechnetium [SNS/S] complexes as potential 5-HT1A receptor imaging agents. *Journal of Biological Inorganic Chemistry*, **2001**, 6, 256-65	3.7	21
16	Oxorhenium mixed-ligand complexes with the 2,6-dimercaptomethylpyridine ligand. Crystal structure of [2,6-dimercaptomethylpyridinato][p-methoxybenzenethiolato]oxorhenium(V). *Inorganica Chimica Acta*, **2000**, 304, 26-32	2.7	13
15	Synthesis and characterization of six-coordinate "3 + 2" mixed-ligand oxorhenium complexes with the o-diphenylphosphinophenolato ligand and tridentate coligands of different N and S donor atom combinations. *Inorganic Chemistry*, **2000**, 39, 2178-84	5.1	14
14	Glutathione Interaction with SNS/S Mixed-Ligand Complexes of Oxorhenium(V): Kinetic Aspects and Characterization of the Products. *Inorganic Chemistry*, **2000**, 39, 4433-4441	5.1	14
13	Oxorhenium phosphinophenolato complexes with model peptide fragments: synthesis, characterization, and stability considerations. *Inorganic Chemistry*, **2000**, 39, 5197-202	5.1	19
12	A "preformed chelate approach" model for coupling amine-modified rhenium and technetium "3+1" mixed ligand complexes to carboxylate residues. *Polyhedron*, **1999**, 18, 3545-3552	2.7	7

List of Publications

11	Synthesis and characterization of five-coordinate rhenium(V) and technetium(V) mixed ligand bifunctional complexes carrying the SNS/S or the SNN/S donor atom set. Crystal structure of ReO{[(C2H5)2NCH2CH2N(CH2CH2S)2](p-H2NPhS)} and ReO{[(CH2)4NCH2CH2NCH2CH2S](p-H2NPhS)}. *Inorganica Chimica Acta*, **1999**, 285, 97-106	2.7	17
10	Study on the formation of mixed ligand oxorhenium and oxotechnetium complexes (SNS/S combination). *Inorganica Chimica Acta*, **1999**, 295, 1-8	2.7	16
9	Characterization and preliminary evaluation of ester-modified technetium-99m SNS/S mixed ligand complexes as potential brain perfusion agents. *Nuclear Medicine and Biology*, **1999**, 26, 297-304	2.1	9
8	Novel Six-Coordinate Oxorhenium(3+) and Oxotechnetium(3+) Mixed-Ligand Complexes Carrying the SNS/PO Donor Atom Set: Synthesis and Characterization. *Inorganic Chemistry*, **1999**, 38, 4197-4202	5.1	34
7	Glutathione-mediated metabolism of technetium-99m SNS/S mixed ligand complexes: a proposed mechanism of brain retention. *Journal of Medicinal Chemistry*, **1999**, 42, 1066-75	8.3	61
6	Cationic [99mTcIII(DIARS)2(SR)2]+ complexes as potential myocardial perfusion imaging agents (DIARS = o-phenylenebis(dimethylarsine);SR- = thiolate). *Journal of Medicinal Chemistry*, **1996**, 39, 1253-61	8.3	20
5	Preparation and characterization of a new rhenium(V) complex containing the methyl ester ligand. *Inorganica Chimica Acta*, **1995**, 240, 291-297	2.7	12
4	Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219-387) labelled with technetium-99m. *European Journal of Nuclear Medicine and Molecular Imaging*, **1994**, 21, 437-44		64
3	Synthesis and characterization of five-co-ordinate rhenium(III) complexes with 2-(diphenylphosphino)ethanethiolate and monothiolate liqands. Crystal structure of [Re(Ph2PCH2CH2S)2(PhCH2S)]. *Journal of the Chemical Society Dalton Transactions*, **1994**, 2437		15
2	Synthesis, radiochemistry and biological evaluation of technetium-99m complexes with 1,8-diamine-3,6-dithiaoctane (DDO) ligands. *International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology*, **1992**, 19, 481-9		1
1	Comparative evaluation of 99mTc-labeled aminothiols as possible brain perfusion imaging agents. *International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology*, **1988**, 15, 215-23		1